Melanoma malignum - Guidelines for diagnostic procedures and therapy;Czerniaki skóry - Zasady postȩpowania diagnostyczno- terapeutycznego

Przeglad Dermatologiczny

Volumn 96, Issue 3, 2009, Pages 193-203

  Ruka, Włodzimierz ^a   Krzakowski, Maciej ^a   Placek, Waldemar ^b,k   Rutkowski, Piotr ^a   Nowecki, Zbigniew I ^a   Fijuth, Jacek ^c   Nasierowska Guttmejer, Anna ^d   Jeziorski, Arkadiusz ^c   Rudnicka, Lidia ^d   Murawa, Paweł ^e   Słuszniak, Janusz ^f   Potemski, Piotr ^c   Zaucha, Renata ^g   Wysocki, Piotr J ^e   Kamińska Winciorek, Grazyna ^h   Bajcar, Stanisław ⁱ   Drosik, Kazimierz ^j   Biernat, Wojciech ^g   Towpik, Edward ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^e GREATER POLAND CANCER CENTRE   (Poland)

^f wi tokrzyskie Centrum Onkologii W Kielcach   (Poland)

^g MEDICAL UNIVERSITY OF GDANSK   (Poland)

^h MEDICAL UNIVERSITY OF SILESIA   (Poland)

ⁱ Dermatomed W Rzeszowie ^*  (Poland)

^j Opolskie Centrum Onkologii   (Poland)

^k Katedra i Klinika Dermatologii   (Poland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; DIAGNOSTIC PROCEDURE; HUMAN; MELANOMA; PRACTICE GUIDELINE; REVIEW; THERAPY EFFECT; TUMOR BIOPSY;

EID: 67651230675     PISSN: 00332526     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Didkowska J., Wojciechowska U., Tarkowski W., Zatoński W.: Nowotwory złośliwe w Polsce w 2005 roku. Centrum Onkologii - Instytut 2007.
2. Ruka W., Nowecki Z., Rutkowski P. (red.).: Czerniaki skóry u dorosłych. Medipage, Warszawa 2005.
3. Dummer R., Hauschild A., Jost L.: ESMO Guidelines Working Group. Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19 (Suppl), ii86-88.
4. Morton D.L., Thompson J.F., Ochran A.J., Mozzillo N., Elashoff R., Essner R. i inni: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355, 1307-1317.
5. Nowecki Z.I., Rutkowski P., Nasierowska-Guttmejer A., Ruka W.: Sentinel lymph node biopsy in clinically NO melanoma patients - one institution experience. Melanoma Res 2003, 13, 35-43.
6. Statius Muller M.G., van Leeuwen P.A., de Lange-De Klerk E.S., van Diest P.J., Pijpers R., Ferwerda C.C. i inni: The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma. Cancer 2001, 91, 2401-2408. (Pubitemid 32552828)
7. Nowecki Z.I., Rutkowski P., Michej W.: The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol 2008, 15, 2223-2234.
8. Doubrovsky A., de Wilt J.H.W., Scolyer R.A., McCarthy W.H, Thompson J.F.: Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma. Ann Surg Oncol 2004, 11, 829-836. (Pubitemid 40568810)
9. van Akkooi A.C.J., Nowecki Z.I., Voit C., Schaefer-Hesterberg G., Michej W., de Wilt J.H.W. i inni: Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008, 248, 949-955.
10. Balch C.M., Soong S.J., Gershenwald J.E., Thompson J.F, Reintagen D.S., Cascinelli N. i inni: Prognostic factors analysis of 17.600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19, 3622-3634.
11. Slingluff C.L. Jr, Flaherty K., Rosenberg S.A., Read P.W.: Cutaneous melanoma, [w:] Cancer. Principles & practice of oncology. V.T. De Vita, S. Hellman, S.A. Rosenberg (red.). Wyd 8. Lippincott, Williams & Wilkins, Philadelphia 2008, 1897-1930.
12. Balch C.M., Buzaid A.C., Soong S.J., Atkins M.B, Casanelli N., Coit D.G. i inni: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19, 3635-3648. (Pubitemid 32786276)
13. Cascinelli N.: Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998, 14, 272-275.
14. Balch C.M., Soong S.J., Smith T., Ross M.I., Urist M.M., Karakousis C.P. i inni: Investigators from the Intergroup Melanoma Surgical Trial. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001, 8, 101-108.
15. Balch C.M., Urist M.M., Karakousis C.P., Smith T.J., Temple W.J., Drzewiecki K. i inni: Efficacy of 2-cm surgical margins for intermediate- thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993, 218, 262-267; discussion 267-269.
16. Banzet P., Thomas A., Vuillemin E.: Wide versus narrow surgical excision in thin (< 2 mm) stage I primary cutaneous malignant melanoma: long term results of a French multicentric prospective randomized trial on 319 patients. Proc Am Assoc Clin Oncol 1993, 12, 387.
17. Khayat D., Rixe O., Martin G., Soubrane C., Banzet M., Bazex J.A. i inni: French Group of Research on Malignant Melanoma. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003, 97, 1941-1946.
18. Ringborg U., Andersson R., Eldh J., Glaumann B., Hafström L., Jacobsson S. i inni: Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996, 77, 1809-1814. (Pubitemid 26125180)
19. Ringborg U, Brahme EM, Drewiecki K.: Randomized trial of a resection margin of 2 cm versus 4 cm for cutaneous malignant melanoma with a tumor thickness of more than 2 mm. World Congress on Melanoma, Vancouver, BC, Canada, September 6-10, 2005.
20. Veronesi U., Cascinelli N., Adamus J., Balch C., Bandiera D., Barchuk A. i inni: Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988, 318, 1159-1162. (Pubitemid 18117695)
21. Thomas J.M., Newton-Bishop J., A'Hern R., Coombes G., Timmons M., Evans J. i inni; United Kingdom Melanoma Study Group; British Association of Plastic Surgeons; Scottish Cancer Therapy Network: Excision margins in high-risk malignant melanoma. N Engl J Med 2004, 350, 757-766.
22. Cohn-Cedermark G., Rutqvist L.E., Andersson R., Breivald M., Ingvar C., Johansson H. i inni: Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000, 89, 1495-1501. (Pubitemid 30727215)
23. Karakousis C.P., Balch C.M., Urist M.M., Ross M.M., Smith T.J., Bartolucci A.A.: Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996, 3, 446-452.
24. Koops H.S., Vaglini M., Suciu S., Kroon B.B., Thompson J.F., Gohl J. i inni: Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593. J Clin Oncol 1998, 16, 2906-2912.
25. Eggermont A.M., Gore M.: Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol 2007, 34, 509-515. (Pubitemid 350245676)
26. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H.: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14, 7-17.
27. Kirkwood J.M., Ibrahim J.G., Sondak V.K., Richards J., Flaherty L.E., Ernstoff M.S. i inni: High and low-dose interferon alpha-2b in high risk melanoma: first analysis of Intergroup Trial E1690/S9111/C9190. J Clin Oncol 2000, 18, 2444-2458. (Pubitemid 30415832)
28. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernsoff M.S. i inni: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S0512/C509801. J Clin Oncol 2001, 19, 2370-2380. (Pubitemid 32391207)
29. Kirkwood J.M., Manola J., Ibrahim J., Sondak V., Ernstoff M.S., Rao U.: A pooled analysis of Eastern Cooperative Group and Intergroup trials of adjuvant high-dose interferon in melanoma. Clin Cancer Oncol 2004, 10, 1670-1677. (Pubitemid 38435557)
30. Eggermont A.M., Suciu S., MacKie R., Ruka W., Testori A., Kruit W. i inni: EORTC Melanoma Group. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005, 366, 1186-1196.
31. Verma S., Quirt I., McCready D., Bak K., Charette M., Iscoe N.: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006, 106, 1431-1442.
32. Atallah E., Flaherty L.: Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005, 6, 185-193.
33. Serrone L., Zeuli M., Sega F.M., Cognetti F.: Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000, 19, 21-34. (Pubitemid 30305516)
34. Middleton M.R., Grob J.J., Aaronson N., Fierlbeck G., Tilgen W., Seiters S. i inni: Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18, 158-166. (Pubitemid 30036349)
35. Rao R.D., Holtan S.G., Ingle J.N., Croghan G.A., Kottschade L.A., Creagan E.T. i inni: Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 2006, 106, 375-382.
36. Eigentler TK, Caroli UM, Radny P, Garbe C.: Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003, 4, 748-759. (Pubitemid 37527210)
37. Smith F.O., Downey S.G., Mapper J.A, Yang I.C., Sherry R.M., Rayal R.E. i inni: Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008, 14, 5610-5618.
38. Atkins M.B., Hsu J., Lee S., Cohen G.I., Flaherty L.E., Sosman J.A.: Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008, 26, 5748-5754.
39. Ives N.J., Stowe R.L., Lorigan P., Wheatley K.: Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007, 25, 5426-5434. (Pubitemid 350232219)